WTA
KALV

Washington Trust Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Washington Trust Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-68
Closed -$1K – 1011
2021
Q4 		$1K Buy
+68
New +$1.08K ﹤0.01% 984

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Washington Trust Advisors's KALV Position: Q1 2022 in Review

Washington Trust Advisors sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 68 shares — an estimated $1K sold.

Washington Trust Advisors first reported a position in KALV in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

  • Washington Trust Advisors reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 68 KalVista Pharmaceuticals shares in Q1 2022, an estimated $1K.
  • Washington Trust Advisors first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Washington Trust Advisors's KalVista Pharmaceuticals position peaked at $1K in Q4 2021.
  • 89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Washington Trust Advisors's 13F filing for Q1 2022, filed 5 May 2022.